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InﬂammationThe objective of this study was to investigate the impact of elevated tissue omega-3 (n-3) polyunsaturated fatty
acids (PUFA) status on age-related glucose intolerance utilizing the fat-1 transgenicmousemodel, which can en-
dogenously synthesize n-3 PUFA from omega-6 (n-6) PUFA. Fat-1 and wild-type mice, maintained on the same
dietary regime of a 10% corn oil diet, were tested at two different ages (2 months old and 8 months old) for var-
ious glucose homeostasis parameters and related gene expression. The older wild-type mice exhibited signiﬁ-
cantly increased levels of blood insulin, fasting blood glucose, liver triglycerides, and glucose intolerance,
compared to the younger mice, indicating an age-related impairment of glucose homeostasis. In contrast, these
age-related changes in glucose metabolism were largely prevented in the older fat-1 mice. Compared to the
older wild-type mice, the older fat-1 mice also displayed a lower capacity for gluconeogenesis, as measured by
pyruvate tolerance testing (PTT) and hepatic gene expression of phosphoenolpyruvate carboxykinase (PEPCK)
and glucose 6 phosphatase (G6Pase). Furthermore, the older fat-1 mice showed a signiﬁcant decrease in body
weight, epididymal fat mass, inﬂammatory activity (NFκ-B and p-IκB expression), and hepatic lipogenesis
(acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) expression), aswell as increased peroxisomal activ-
ity (70-kDa peroxisomal membrane protein (PMP70) and acyl-CoA oxidase1 (ACOX1) expression). Altogether,
the older fat-1 mice exhibit improved glucose homeostasis in comparison to the older wild-type mice. These
ﬁndings support the beneﬁcial effects of elevated tissue n-3 fatty acid status in the prevention and treatment
of age-related chronic metabolic diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The increasing number of elder people associated with sedentary
lifestyle presents unprecedented public health and societal challenges.
Several studies have demonstrated that glucose tolerance declines pro-
gressively with age in humans and othermammals [1,2]. The pathogen-
esis of age-related glucose intolerance has been associated with
increased body fat mass and visceral fat content [3], physical inactivity,
and changes in dietary patterns [4]. Impairments in both lipid metabo-
lism and glucose homeostasis are often implicated in age-related
disorders and reduced life expectancy [1,5,6].yunsaturated fatty acids; PEPCK,
phosphatase; ACC, acetyl-CoA
eroxisomal membrane protein;
mor necrosis factor α; PAI-1,
emoattractant protein; IKK, IκB
ARα, peroxisome proliferator-
raphy; GTT, glucose tolerance
e & Technology, Department of
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).
ights reserved.There is interplay among lipid metabolism, inﬂammation, and
insulin sensitivity. In adipose tissue, insulin resistance impairs the
insulin-induced suppression of lipolysis [7], leading to triglyceride
(TG) accumulation in tissues that typically do not specialize in fat stor-
age, such as the liver, skeletal muscle, and pancreas. This ectopic fat ac-
cumulationmay result in a low-grade inﬂammatory state, characterized
by the increased production of pro-inﬂammatory molecules, such as
tumor necrosis factor α (TNF-α), plasminogen activator inhibitor-1
(PAI-1), monocyte chemoattractant protein (MCP)-1, as well as the
activation of inﬂammatory signaling pathways, such as IKK, c-jun kinase
(JNK) and nuclear factor-κB (NF-κB) [8,9]. Consequently, chronic
inﬂammation may lead to impaired responses of peripheral tissues to
insulin and thereby cause glucose intolerance.
The amount and type of dietary fat differentially affect glucose
homeostasis; in particular, saturated fat is known to contribute to the
development of glucose intolerance and insulin resistance [10–13]. In
contrast, omega-3 polyunsaturated fatty acids (n-3 PUFA) have been
shown to improve insulin sensitivity [14–16]. Omega-3 PUFA is a natu-
ral ligand for the transcription factor peroxisome proliferator-activated
receptor-α (PPARα), which can increase the expression of enzymes
involved in the beta-oxidation of fatty acids [17,18]. This increased
oxidation of fatty acids in the liver may be due to the induction of
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interactions can reduce fat deposition in the liver and plasma triglycer-
ide levels. Furthermore, through the activation of PPAR transcription
factors, n-3 PUFA can suppress inﬂammatory signaling pathways such
as NF-κB, inhibiting the production of pro-inﬂammatory cytokines
[19]. It is therefore possible that the lipogenesis-suppressing and anti-
inﬂammatory properties of n-3 PUFA afford them the capability to
prevent age-related glucose intolerance.
To eliminate the potential confounding factors of diet, we utilized
the transgenic fat-1 mouse model, which expresses the C. elegans fat-1
gene and is capable of endogenously synthesizing n-3 PUFA from n-6
PUFA without the need for dietary supplementation [20,21]. In this
study, we investigated the inﬂuence of elevated tissue n-3 PUFA status
on age-related glucose tolerance.
2. Methods
2.1. Animal model
Transgenic fat-1micewere generated as previously described previ-
ously [20] and backcrossed onto a C57BL/6 background. Male fat-1
transgenic mice and non-transgenic littermate controls were divided
in four study groups: 2-month-old wild-type (WT-2M), 2-month-old
fat-1 (FAT1–2M), 8-month-old WT (WT-8M), and 8-month-old fat-1
(FAT1–8M). The phenotype of the fat-1 transgenic mice (as indicated
by increased tissue n-3 PUFA) was conﬁrmed by fatty acid analysis
using gas chromatography (GC).WT and fat-1 animalsweremaintained
on a 10% corn oil diet (AIN-76A, 10% corn oil, w/w) ad libitum and
housed in temperature- and humidity-controlled conditions with a
12-h light/dark cycle. All animal procedures were carried out in
accordance with the guidelines set by the Massachusetts General
Hospital Animal Committee and with IACUC approval.
2.2. Determination of food intake
Food intake was measured twice a week during the last month be-
fore the sacriﬁce. Mice were food deprived for 6 hours (from 1 pm to
7 pm) and the food ingestion was determined over the next 12 hours.
2.3. Tissue sample collection
At the end of the experimental period, all mice were sacriﬁced after
6 hours of fasting and blood samples were collected and centrifuged.
Serum aliquots were used to measure insulin (Millipore #EZRMI-13K),
triglycerides (Abcam #Ab65336), and cholesterol (Abcam #Ab65390).
The epididymal fat pad was removed and weighed. Other tissues and
organs were harvested and frozen for future analysis.
2.4. Fatty acid analysis
The fatty acid proﬁles of liver and tail samples were determined by
gas chromatography, as described previously [22]. In brief, tissue
(~10 mg) was ground into powder under liquid nitrogen and subjected
to fatty acid methylation by 14% boron triﬂuoride (BF3)-methanol re-
agent (Sigma-Aldrich) at 100 °C for 1 h. Fatty acid methyl esters were
analyzed with the Agilent HP6890N gas chromatography system
equipped with a ﬂame ionization detector (Agilent Technologies, Palo
Alto, CA). The fatty acid peaks were identiﬁed by comparing their rela-
tive retention times with the commercial mixed standards (Nu-Chek
Prep, Elysian, MN), and the area percentages for all resolved peaks
were analyzed using GC Chemstation software.
2.5. Measurement of hepatic triglyceride content
Frozen tissues (200 mg)were homogenized in 1.5 mL of phosphate-
buffered saline. The protein concentration of homogenate wasdetermined and an aliquot of 300 mL was extracted with 5 mL of
chloroform/methanol (2:1) and 0.5 mL of 0.1% sulfuric acid. An aliquot
of the organic phase was collected, dried under nitrogen and re-
suspended in 2% Triton X-100. TG content was determined using a
Triglyceride Quantiﬁcation Kit (BioVision, Mountain View, CA) follow-
ing the manufacturer's protocol.
2.6. Intraperitoneal glucose tolerance test
The intraperitoneal glucose tolerance test (GTT) was performed
after 6 hours of fasting. After collection of an unchallenged sample
(time 0), 20% glucose (2.0 g/kg body weight) was administered into
the peritoneal cavity. Through a small cut at the tail tip, blood samples
were collected at 15, 30, 45, 60, 75 and 90 minutes after the injection
of glucose for the determination of glycemia.
2.7. Intraperitoneal pyruvate tolerance test
The intraperitoneal pyruvate tolerance test (PTT) was performed
after 6 hours of fasting. After collection of an unchallenged sample
(time 0), the pyruvate solution (2.0 g/kg body weight) was adminis-
tered into the peritoneal cavity. Tail blood samples were collected at
15, 30, 45, 60, 75 and 90 minutes for the determination of glucose
concentration in the blood.
2.8. Real-time PCR analysis
The mRNA content of PMP70 and ACOX1 were measured in liver
samples, as previously described [23]. Real-time PCR data were
analyzed using the Stratagene MX3005P qPCR System (Agilent
Technologies, Palo Alto, CA).
2.9. Immunoblot analysis
The liver was homogenized and used for immunoblot analysis, as
previously described [24]. Fifty micrograms of protein was loaded
onto a 12% acrylamide gel, subjected to SDS-PAGE, and then transferred
onto nitrocellulose membranes. Membranes were then blocked and
probed with the appropriate antibodies. Antibodies for p-ACC, ACC,
NFκB, p-Iκb and β-actin were obtained from Cell Signaling Technology
(Danvers,MA) and antibodies for PEPCK, G6Pase and FASwere obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Band intensities were
quantiﬁed by optical densitometry (Scion Image, Frederick, MD).
2.10. Statistical analysis
Results are presented asmeans ± SEM. All results were analyzed by
two-way ANOVA.When necessary, these analyses were complemented
by the Bonferroni test to determine the signiﬁcance of individual
differences. The level of signiﬁcance was set at p b 0.05.
3. Results
3.1. Changes in metabolic parameters with aging
The genotypes of the wild-type and fat-1 transgenic mice were con-
ﬁrmed by GC analysis of fatty acid composition. The fat-1 mice used in
this study exhibited more than twice the hepatic levels of n-3 PUFA,
mainly DHA, compared to the WT mice (6.58 ± 0.67 vs 2.91 ± 0.36,
p b 0.05), while the n-6/n-3 PUFA ratio was signiﬁcantly reduced from
13.30 ± 0.62 in WT mice to 5.69 ± 0.43 in fat-1 mice. Both the two-
month-old and eight-month-old groups exhibited similar fatty acid
proﬁles.
A number of metabolic parameters changed in the WT mice with
aging. Speciﬁcally, bodyweight, epididymal fat padmass, blood glucose,
blood insulin, plasma triglycerides, and plasma cholesterol levels were
Fig. 2. Effect of aging and n-3 PUFA on glucose tolerance. (A) Blood glucose levels during
glucose tolerance testing (GTT); (B) Calculated area under curve (AUC) from GTT results;
(C) Blood insulin levels duringGTT, taken at t = 0, 45, and 90mins.WT-2M: 2-month-old
wild-type mice; FAT1-2M: 2-month-old fat-1 mice; WT-8M: 8-month-old wild-type
mice; FAT1-8M: 8-month-old fat-1 mice. (*p b 0.05 for FAT1–8M versus WT-8M; two
way ANOVA, n = 8).
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pared to the 2-month-old WT mice (Fig. 1). These age-related changes
were much less pronounced in the older fat-1 mice (FAT1–8M) com-
pared to the younger fat-1 mice (Fig. 1); interestingly, blood glucose
levels were slightly lower in the older fat-1mice (Fig. 1C). The profound
differences in these metabolic parameters between the older fat-1 and
WT mice were not observed in the younger mice. No signiﬁcant
difference in food intake was observed between the two genotypes at
either time point.
3.2. Age-related impairments in glucose homeostasis are prevented in
fat-1 mice
To examine the potential changes in glucose homeostasis, GTT, PTT,
and related gene expression assays were performed on all groups. GTT
results showed that theWT-8M group, but not the FAT1–8M group, ex-
hibited a signiﬁcantly increased area under the curve (AUC) of glycemia,
compared to the younger mice (Fig. 2A and B). Accordingly, blood insu-
lin levels during GTT were signiﬁcantly higher in WT-8M than in the
other groups and remained elevated for more than 90 minutes. In con-
trast, the blood insulin levels in FAT1–8Mmiceweremuch less elevated
during GTT and returned to baseline levels within 90 minutes (Fig. 2C).
PTT results showed that the WT-8M group had signiﬁcantly higher
blood glucose concentrations in response to the challenge, compared
to the other groups, indicating an increased capacity for gluconeogene-
sis in the WT-8M mice (Fig. 3A). To assess the potential changes in the
enzymes responsible for gluconeogenesis, wemeasured the hepatic ex-
pression levels of phosphoenolpyruvate carboxykinase (PEPCK) and
glucose-6-phosphatase (G6Pase). The results showed a marked in-
crease in the hepatic expression of PEPCK (Fig. 3B) and G6Pase
(Fig. 3C) in the WT-8M mice compared with the younger WT mice,
whereas no signiﬁcant increase in the expression of these two genes
was observed in the FAT1–8M group.
3.3. Age-related hepatic lipogenesis and inﬂammation are reduced in
fat-1 mice
In order to determine the potential differences in the lipogenic
capacity of the liver, we measured the hepatic phosphorylation of
acetyl-CoA carboxylase (ACC) and expression levels of fatty acid syn-
thase (FAS) in all groups. The WT-8M mice exhibited signiﬁcantly
higher levels of both phosphorylated ACC and FAS expression compared
with the younger WT mice, indicating an increased capacity forFig. 1. Changes in metabolic characteristics with aging. The four experimental groups were me
mass (% of bodyweight); (C) blood glucose; (D) blood insulin; (E) plasma triglycerides; (F) plasm
by Bonferroni test, n = 8).lipogenesis in the WT-8M mice (Fig. 4A and B). Interestingly, the
FAT1–8M mice did not show any increases in ACC and FAS, compared
to the younger fat-1mice (Fig. 4A and B). Accordingly, hepatic triglycer-
ide levelswere shown to bemuchhigher in theWT-8Mmice than in theasured for the following metabolic parameters: (A) body weight; (B) epididymal fat pad
a cholesterol.WT: wild-typemice; FAT1: transgenic fat-1mice (twowayANOVA followed
Fig. 3. Effect of aging and n-3 PUFA on gluconeogenesis. (A) Blood glucose levels during pyruvate tolerance testing (PTT); (B) Western blotting showing the hepatic expression of PEPCK
and (C) G6Pase; bars show quantiﬁcation of total protein normalized by total β-actin.WT-2M: 2-month-old wild-type mice; FAT1-2M: 2-month-old fat-1 mice; WT-8M: 8-month-old
wild-type mice; FAT1–8M: 8-month-old fat-1 mice. (*p b 0.05 for FAT1- 8M versus WT-8M; Two way ANOVA, n = 8).
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mice, compared to the younger fat-1 mice (Fig. 4C).
To evaluate peroxisomal function, we determined the mRNA levels
of 70-kDa peroxisomal membrane protein (PMP70), a peroxisome
membrane protein, and acyl-CoA oxidase 1 (ACOX1), which catalyzes
the ﬁrst step of the fatty acid β-oxidation in peroxisomes. The expres-
sion of both genes was signiﬁcantly increased in the FAT1–8M group,
but not in theWT-8M group, compared to the younger mice, indicating
increased peroxisomal function in the FAT1–8M mice (Fig. 5A and B).
To evaluate the potential differences in the inﬂammatory response
pathways, we examined the hepatic expression of NF-κB and p-IκB.
The results showed that expression levels of NF-κB and p-IκB were
greatly increased in WT-8M mice compared to the younger WT mice,
whereas the increase of NF-κB and p-IκB expression in the FAT1–8M
mice was much less pronounced (Fig. 6).
4. Discussion
The results presented here demonstrate markedly impaired glu-
cose homeostasis in older mice, associated with increased hepaticFig. 4. Effect of aging and n-3 PUFA on lipogenesis. Western blotting showing the hepatic expre
ylation or total protein normalized by total ACC and β-actin, respectively; (C) hepatic triglycerid
Bonferroni test, n = 8).gluconeogenesis, lipogenesis, and inﬂammatory response. Most im-
portantly, these changes can be signiﬁcantly reduced or prevented
in fat-1 mice with elevated tissue status of n-3 PUFA.
A unique feature of this study is the utilization of the fat-1 transgenic
mousemodel. The fat-1mice allowedus to create twodistinct tissue n-3
PUFA levels, without the need for supplementation with different diets,
so that we can examine the authentic effect of elevated tissue n-3 PUFA
without potential confounding factors of the diet. This is particularly
important for aging studies that typically require long-term feeding,
which may introduce variations in food components, such as other
fats, antioxidants, vitamins, oxidized compounds, and contaminants
[21]. The fat-1 mouse model has been widely used to study the health
effects of elevated tissue n-3 PUFA status [21]; in particular, recent
fat-1 studies have shown beneﬁcial effects on diabetes and obesity
development [25,26].
Our observations that increased tissue n-3 PUFA can improve glu-
cose and lipid homeostasis are consistent with previous reports
[27–30]. The beneﬁcial effects of n-3 PUFA on glucose homeostasis in
our study are evidenced by a decrease in blood glucose (as shown by
the decreased AUC during GTT), blood insulin, plasma triglycerides,ssion of phosphorylated ACC (A) and FAS (B). Bars show quantiﬁcation of total phosphor-
e content.WT: wild-typemice; FAT1: transgenic fat-1mice (two way ANOVA followed by
Fig. 5.Effect of aging and n-3 PUFA on peroxisomal activity.mRNAexpression of PMP70 (A) andACOX1 (B).WT: wild-typemice; FAT1: transgenic fat-1mice (twowayANOVA followed by
Bonferroni test, n = 8).
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by PTT results showing decreased liver glucose production. As hepatic
gluconeogenesis is a major determinant of blood glucose levels, the re-
duced capacity for gluconeogenesis in older fat-1 mice — as evidenced
by the PTT results and the decreased expression of two key enzymes
of gluconeogenesis, PEPCK and G6Pase—may be one of the underlying
mechanisms contributing to the improved glucose tolerance of older
fat-1 mice. The inhibitory effects of n-3 PUFA on gluconeogenesis and
PEPCK expression are aligned with previous ﬁndings in n-3 PUFA
supplementation studies [17,31,32].
Our study also revealed amajor effect of elevated tissue n-3 PUFA on
lipid metabolism, as shown by a decrease in lipid synthesis and an in-
crease in fatty acid oxidation in the older fat-1 mice. The decreased
lipid synthesis was reﬂected by the reduced expression of two impor-
tant enzymes for lipogenesis, ACC and FAS, as well as lowered hepatic
triglyceride content. Our ﬁndings are supported by previous studies
showing that the activity of enzymes involved in lipid synthesis isFig. 6. Effect of aging and n-3 PUFA on inﬂammatory response. Western blotting showing
the hepatic expression of NFkB and phosphorylated IkB (A). Bars show quantiﬁcation of
NF-κB (B) and p-IkB (C) normalized by total β-actin in the liver, respectively.WT: wild-
type mice; FAT1: transgenic fat-1 mice (two way ANOVA followed by Bonferroni test,
n = 8).decreased in response to n-3 PUFA supplementation [33,34]. The in-
creased fatty acid oxidation in older fat-1 micewas indicated by greater
hepatic expression of PMP-70, a marker of increased peroxisome
proliferation, and ACOX-1, the rate-limiting enzyme for peroxisomal
beta-oxidation of FA [35]. In fact, previous studies have shown that n-3
PUFA supplementation increases peroxisome content and activity,
leading to increased FA beta-oxidation [18,36,37]. Both reduced lipo-
genesis and increased FA oxidation are known to be stimulated by
activation of PPARα, a transcriptional factor involved in the control
of peroxisomal function, for which n-3 PUFA are a natural ligand
[38–40]. Furthermore, previous studies have shown that excessive
amounts of saturated FA and n-6 PUFA impair the transduction of insu-
lin signaling in various tissues [41–44]. It is therefore conceivable that
decreased fatty acid synthesis and reduced n-6 PUFA tissue content, as
seen in the older fat-1 mice, may contribute to improved insulin
sensitivity.
Chronic inﬂammation is a pathological characteristic of aging and in-
creased inﬂammatory cytokines, such as interleukin-6 (IL-6), IL-1β, and
tumor necrosisα (TNF-α), have been linked tomany age-related disor-
ders [45,46]. It is well known that chronic inﬂammation can disrupt in-
sulin signaling, leading to insulin resistance in metabolic tissues
[47–49]. Production of inﬂammatory cytokines is stimulated by the
phosphorylation of IKB and the activation of transcriptional factor
NFκB. Although we did not directly measure cytokine levels, our ﬁnd-
ings that phosphorylated IKB and NFκB are increased in the older WT
mice, but only slightly changed in older fat-1 mice, suggest that
increased tissue n-3 PUFA suppresses the age-related inﬂammatory
response. The decreased production of inﬂammatory cytokines has
been well documented in the fat-1 mouse model [50,51].
In summary, this study provides evidence that elevated tissue n-3
PUFA status can improve age-related glucose intolerance. The underly-
ing mechanisms for this effect may include reduced hepatic gluconeo-
genesis and lipogenesis, increased peroxisomal activity, and decreased
inﬂammatory response. These ﬁndings support the beneﬁcial effects of
elevated tissue n-3 fatty acid status in the prevention and treatment of
age-related chronic metabolic diseases, such as insulin resistance and
type 2 diabetes.
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